206 related articles for article (PubMed ID: 26569093)
1. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
[TBL] [Abstract][Full Text] [Related]
2. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
3. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
[TBL] [Abstract][Full Text] [Related]
6. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Bou Akl I; Matar M; Khalil PB; Massoud R; Ghaoui N; Karout L; Zahreddine A; Bazarbachi A; El-Cheikh J
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):371-376.e1. PubMed ID: 32151585
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
9. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
10. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Przepiorka D; van Besien K; Khouri I; Hagemeister F; Samuels B; Folloder J; Ueno NT; Molldrem J; Mehra R; Körbling M; Giralt S; Gajewski J; Donato M; Cleary K; Claxton D; Braunschweig I; Andersson B; Anderlini P; Champlin R
Ann Oncol; 1999 May; 10(5):527-32. PubMed ID: 10416001
[TBL] [Abstract][Full Text] [Related]
11. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
El-Najjar I; Boumendil A; Luan JJ; Bouabdallah R; Thomson K; Mohty M; Colombat P; Biron P; Tilly H; Pfreundschuh M; Cordonnier C; Sureda A; Cahn JY; Vernant JP; Gribben J; Cook G; Haynes AP; Ferrant A; Finel H; Montoto S; Dreger P;
Ann Oncol; 2014 Nov; 25(11):2224-2229. PubMed ID: 25193988
[TBL] [Abstract][Full Text] [Related]
12. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Zaucha R; Gooley T; Holmberg L; Gopal AK; Press O; Maloney D; Bensinger WI
Leuk Lymphoma; 2008 Oct; 49(10):1899-906. PubMed ID: 18949614
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Vose JM; Bierman PJ; Loberiza FR; Enke C; Hankins J; Bociek RG; Chan WC; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2013 Jan; 19(1):123-8. PubMed ID: 22940055
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Salhotra A; Mei M; Stiller T; Mokhtari S; Herrera AF; Chen R; Popplewell L; Zain J; Ali H; Sandhu K; Budde E; Nademanee A; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):287-292. PubMed ID: 30227232
[TBL] [Abstract][Full Text] [Related]
18. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients.
Deveci B; Ateşoğlu EB; Bayrak E; Kublashvili G; Toptaş T; Saba R; Gülbaş Z
Transplant Proc; 2023; 55(1):235-241. PubMed ID: 36639277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
